Drug Addiction Pipeline Review, H2 2018 - Therapeutic Assessment of 25 Companies & Drug Profile Activity - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Drug Addiction - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Drug Addiction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 31 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.
Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Drug Addiction - Overview Drug Addiction - Therapeutics Development Drug Addiction - Therapeutics Assessment Drug Addiction - Companies Involved in Therapeutics Development Drug Addiction - Drug Profiles Drug Addiction - Dormant Projects Drug Addiction - Discontinued Products Drug Addiction - Product Development Milestones Appendix
Companies FeaturedAddex Therapeutics Ltd Aelis Farma SAS Aphios Corp BioCorRx Inc Charleston Laboratories Inc Chiesi Farmaceutici SpA Consegna Pharma Inc Curemark LLC Egalet Corp Embera NeuroTherapeutics Inc F. Hoffmann-La Roche Ltd Heptares Therapeutics Ltd IMV Inc InterveXion Therapeutics LLC Intra-Cellular Therapies Inc Johnson & Johnson Kyorin Pharmaceutical Co Ltd Kyowa Hakko Kirin Co Ltd Omeros Corp Orexigen Therapeutics Inc Ovid Therapeutics Inc P2D Inc Saniona AB SpringWorks Therapeutics LLC Zynerba Pharmaceuticals Inc For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/s358ns/drug_addiction?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006224/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Addiction Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/25/2018 05:45 PM/DISC: 09/25/2018 05:45 PM